You are here

FSME IMMUN NEW Follow-up to Study 205 in Children Aged 6 to 16 Years

Last updated on March 15, 2019

FOR MORE INFORMATION
Study Location
Neuschwanstein Strasse 5
Augsburg, , D-86163 Germany
Contact
1-800-718-1021
Eligibility criteria
Condition
The disease, disorder, syndrome, illness, or injury that is being studied.
Tick-borne Encephalitis
Sex
Females and Males
Age
Pediatric Trials: 0-17 Years
Adult Trials: 18+ Years
6-16 years
Inclusion criteria
The factors, or reasons, that allow a person to participate in a clinical study.
Show details

All volunteers who participated in Baxter study 205 and received two vaccinations will be
invited to participate. Male and female children will be eligible for participation in this
study if:

- They received two vaccinations with one of the three different dosages of FSME IMMUN
NEW during the course of Baxter study 205

- They and/or their legal guardian understand the nature of the study, agree to its
provisions and give written informed consent

Exclusion criteria
The factors, or reasons, that prevent a person from participating in a clinical study.
Show details

There are no specific exclusion criteria for this study entry. However volunteers will be
assessed for eligibility to receive a third vaccination.

Volunteers will be excluded from vaccination and consecutive visits in this study if they:

- Are not clinically healthy, (i. e. the physician would have reservations vaccinating
with FSME IMMUN NEW outside the scope of a clinical trial)

- Have already been administered a third TBE vaccination elsewhere after the two
vaccinations in Baxter study 205

- Have had an allergic reaction to one of the components of the vaccine since the last
vaccination in Baxter study 205

- Suffer from a disease (e.g. autoimmune disease) or are undergoing a form of treatment
(e.g. systemic corticosteroids, chemotherapeutics) that can be expected to influence
immunological functions

- Have received banked human blood or immunoglobulins within one month of study entry

- Are known to be HIV positive (a special HIV test is not required for the purpose of
the study) since the last visit of Baxter study 205

- Have had a vaccination against yellow fever and / or Japanese B-encephalitis since the
last visit in Baxter study 205

- Had received an investigational new drug within 6 weeks prior to study start

- If female and capable of bearing children - have a positive pregnancy test at the
first medical examination

NCT00161889
Pfizer
Completed
FSME IMMUN NEW Follow-up to Study 205 in Children Aged 6 to 16 Years

NEED INFO?

Questions about a trial? Call or email to reach a Pfizer Clinical Trial Contact Center Representative

Pfizer Clinical Trials Contact Center

1-800-718-1021

[email protected]

call now

Try a new search

Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.

FOR MORE INFORMATION

Contact a representative by phone, email, or visiting the study website. Please see the references below:

BY PHONE

Pfizer Clinical Trials Contact Center

1-800-718-1021

BY EMAIL

Contact

[email protected]

Call Now